Multidrug-Resistant Bacteria on Critically Ill Patients with Sepsis at Hospital Admission: Risk Factors and Effects on Hospital Mortality
Marcelo de Oliveira Maia,Carlos Darwin Gomes da Silveira,Maura Gomes,Sérgio Eduardo Soares Fernandes,Rosália Bezerra de Santana,Daniella Queiroz de Oliveira,Felipe Ferreira Pontes Amorim,Francisco de Assis Rocha Neves,Fábio Ferreira Amorim
DOI: https://doi.org/10.2147/IDR.S401754
2023-03-24
Infection and Drug Resistance
Abstract:Marcelo de Oliveira Maia, 1, 2 Carlos Darwin Gomes da Silveira, 1, 3, 4 Maura Gomes, 5 Sérgio Eduardo Soares Fernandes, 3 Rosália Bezerra de Santana, 3 Daniella Queiroz de Oliveira, 3 Felipe Ferreira Pontes Amorim, 4 Francisco de Assis Rocha Neves, 2 Fábio Ferreira Amorim 1, 2 1 Graduation Program in Health Sciences of School Health Sciences, Escola Superior de Ciências da Saúde (ESCS), Brasília, Federal District, Brazil; 2 Graduation Program in Health Sciences, University of Brasília (UnB), Brasília, Federal District, Brazil; 3 Medical School, Escola Superior de Ciências da Saúde (ESCS), Brasília, Federal District, Brazil; 4 Medical School, Centro Universitário do Planalto Central (UNICEPLAC), Brasília, Federal District, Brazil; 5 Intensive Care Unit, Hospital Santa Luzia Rede D'Or São Luiz, Brasília, Federal District, Brazil Correspondence: Fábio Ferreira Amorim, Coordenação de Pesquisa e Comunicação Científica - Escola Superior de Ciências da Saúde, SMHN Quadra 03, conjunto A, Bloco 1 - Edifício FEPECS, Brasília, Federal District, 70701-907, Brazil, Email Marcelo de Oliveira Maia, Programa de Pós-Graduação em Ciências da Saúde - Escola Superior de Ciências da Saúde, SMHN Quadra 03, conjunto A, Bloco 1 - Edifício FEPECS, Brasília, Federal District, 70701-907, Brazil, Email Purpose: To evaluate the effect of MDRO infection on hospital mortality and the risk factors among critically ill patients with sepsis at hospital admission. Patients and Methods: A cross-sectional study was performed between April 2019 and May 2020, followed by a cohort to evaluate hospital mortality that prospectively included all consecutive patients 18 years or older with sepsis admitted within 48 hours of hospital admission to an adult ICU in Brazil. Patients' characteristics, blood samples within one hour of ICU admission, and microbiological results within 48h of hospital admission were collected. In addition, descriptive statistics, binary logistic regression, and propensity score matching were performed. Results: At least one MDRO was isolated in 85 patients (9.8%). The extended-spectrum beta-lactamase-producing Enterobacterales are the most frequent organism (56.1%). Hypoxemic acute respiratory failure (OR 1.87, 95% CI 1.02– 3.40, p = 0.04), Glasgow Coma Score below 15 (OR 2.57, 95% CI 1.38– 4.80, p < 0.01), neoplasm (OR 2.66, 95% CI 1.04– 6.82, p = 0.04) and hemoglobin below 10.0 g/dL (OR 1.82, 95% CI 1.05– 3.16, p = 0.03) were associated with increased MDRO. Admission from the Emergency Department (OR 0.25, 95% CI 0.14– 0.43, p < 0.01) was associated with decreased MDRO. In the multivariate analysis, MDRO at hospital admission increased hospital mortality (OR 2.80, 95% CI 1.05– 7.42, p = 0.04). After propensity score-matching adjusted to age, APACHE II, SOFA, and dementia, MDRO at hospital admission was associated with significantly high hospital mortality (OR 2.80, 95% CI 1.05– 7.42, p = 0.04). The E-value of adjusted OR for the effect of MDRO infection on hospital mortality was 3.41, with a 95% CI of 1.31, suggesting that unmeasured confounders were unlikely to explain the entirety of the effect. Conclusion: MDRO infection increased hospital mortality, and MDRO risk factors should be accessed even in patients admitted to ICU within 48 hours of hospital admission. Keywords: drug resistance, multiple, bacterial, community-acquired infections, sepsis, risk factors, mortality Sepsis remains a significant cause of death in critically ill patients, with more than a third of septic patients dying during the hospital stay. Furthermore, it accounts for a considerable amount of the intensive care unit (ICU) costs. 1–3 In an attempt to reduce mortality and morbidity from sepsis and septic shock, initiatives, such as the Surviving Sepsis Campaign, were established to support the choice of therapies, improving the care of sepsis. 4–7 Despite the advances in its knowledge and management, sepsis treatment remains a challenge. Nowadays, antibiotics are still the only effective drugs against sepsis, mainly when used early. Indeed, the outcomes of patients with sepsis, regardless of the resistance condition of the agent causing the infection, improve significantly if timely and appropriate therapy. On the other hand, inappropriate antibiotic therapy is undoubtedly associated with several serious consequences, including increased mortality. 7–12 However, the treatment with broad-spectrum antibiotics in patients with a low risk of multidrug-resistant organisms (MDRO) infection may expose patients to the risk of the emergence of drug-resistant -Abstract Truncated-
pharmacology & pharmacy,infectious diseases